Edgemont Pharmaceuticals
Specialty drugs for psychiatric and neurological disorders.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
$5.0m | Debt | ||
| Total Funding | 000k | ||
Edgemont Pharmaceuticals is a specialty pharmaceutical company founded in 2006. The company focuses on developing and commercializing novel drug formulations for the treatment of psychiatric disorders. Its main therapeutic areas include major depressive disorder, bulimia nervosa, obsessive-compulsive disorder, and panic disorder.
Headquartered in Austin, Texas, Edgemont operates within the biotechnology industry, aiming to provide improved versions of widely-prescribed products to address the needs of neurological patients. The company's business model centers on acquiring and developing these specialized pharmaceuticals. Over its history, Edgemont Pharmaceuticals raised $14.8 million in funding, with notable investors including Spindletop Capital. The company was later acquired by Alvogen Group.
Leadership at the company included Doug Saltel. Edgemont's strategy involves creating therapies that help patients manage depression and anxiety-related problems more effectively. By focusing on novel formulations, the company seeks to enhance existing treatments available in the neuroscience field.
Keywords: specialty pharmaceutical, psychiatric disorders, neurological disorders, drug development, neuroscience, major depressive disorder, obsessive-compulsive disorder, panic disorder, biotechnology, drug formulation, Alvogen Group, Spindletop Capital, commercialization, therapies for depression, anxiety treatment, CNS disorders